ダウンロード数: 483

このアイテムのファイル:
ファイル 記述 サイズフォーマット 
j.jconrel.2014.09.011.pdf1 MBAdobe PDF見る/開く
タイトル: Self-assembling lipid modified glycol-split heparin nanoparticles suppress lipopolysaccharide-induced inflammation through TLR4-NF-κB signaling.
著者: Babazada, Hasan
Yamashita, Fumiyoshi  kyouindb  KAKEN_id  orcid https://orcid.org/0000-0002-3503-8696 (unconfirmed)
Yanamoto, Shinya
Hashida, Mitsuru  KAKEN_id
著者名の別形: 橋田, 充
キーワード: Inflammation
Heparin nanoparticles
Toll-like receptors
Desulfation
Macrophage
Nuclear factor-κB
発行日: 28-Nov-2014
出版者: Elsevier BV
誌名: Journal of controlled release
巻: 194
開始ページ: 332
終了ページ: 340
抄録: Self-assembling heparin nanoparticles have attracted much attention as promising drug carriers for various drugs, genes and imaging agents. In the present investigation, we found that heparin nanoparticles are selective Toll-like receptor 4 (TLR-4) antagonists and have a much greater anti-inflammatory effect than native heparin. More specifically, we developed self-assembling nanoparticles composed of glycol-split heparin/d-erythro-sphingosine conjugates (NAHNP), characterized their physicochemical properties and anti-inflammatory effect in vitro. Unlike native heparin, NAHNP significantly inhibited lipopolysaccharide-induced activation of MyD88-dependent NF-κB signaling pathway and production of pro-inflammatory cytokines such as TNF-alpha from mouse macrophages with IC50=0.019mg/mL. Furthermore, we investigated the structure-activity relationship of the conjugates and identified the length of attached alkyl chains of d-erythro-sphingosine to be critical for anti-inflammatory effect. Decrease in alkyl chain length of NAHNP resulted in loss of inhibitory activity. In line with these findings, 6-O-sulfate groups of d-glucosamine residue were essential for effective inhibition, while removal of 2-O-sulfo and 3-O-sulfo groups as well as replacement of N-sulfo groups with N-acetyl did not alter anti-inflammatory activity. Therefore, NAHNP would be a promising candidate in acute and chronic inflammatory disorders, in addition to the nature of a drug carrier.
著作権等: © 2014 Elsevier B.V.
This is not the published version. Please cite only the published version.
この論文は出版社版でありません。引用の際には出版社版をご確認ご利用ください。
URI: http://hdl.handle.net/2433/191264
DOI(出版社版): 10.1016/j.jconrel.2014.09.011
PubMed ID: 25234820
出現コレクション:学術雑誌掲載論文等

アイテムの詳細レコードを表示する

Export to RefWorks


出力フォーマット 


このリポジトリに保管されているアイテムはすべて著作権により保護されています。